Trials / Completed
CompletedNCT05489328
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
A PHASE 1, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 394 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to describe the safety and immunogenicity of Pneumococcal Conjugate Formulations in healthy adults 18 through 49 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Candidate-1 | Biological |
| OTHER | Candidate-2 | Biological |
| OTHER | Candidate-3 | Biological |
| OTHER | Candidate-4 | Biological |
| OTHER | Candidate-5 | Biological |
| OTHER | Candidate-6 | Biological |
| OTHER | Candidate Control | Biological |
| BIOLOGICAL | 13vPnC | 13-valent pneumococcal conjugate vaccine |
| BIOLOGICAL | PCV15 | 15-valent pneumococcal conjugate vaccine |
Timeline
- Start date
- 2022-08-15
- Primary completion
- 2022-10-07
- Completion
- 2022-10-07
- First posted
- 2022-08-05
- Last updated
- 2024-04-18
- Results posted
- 2024-04-18
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05489328. Inclusion in this directory is not an endorsement.